{"entity":{"type":"insider","cik":"0001720685","url":"/insider/0001720685","json_url":"/insider/0001720685.json","name":"Katabi Maha","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":13,"first":"2020-07-01","last":"2024-03-25","span_basis":"filed_date"},"name_variants":[{"name":"Katabi Maha","source":"filing","n_filings":13,"first_seen":"2020-07-01","last_seen":"2024-03-25"}],"transactions":[{"id":2075987,"accession":"0001104659-24-038589","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-24-038589","line_url":"/filing/0001104659-24-038589#line-6","is_derivative":false,"issuer_cik":"0001720685","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001720685","owner_cik":"0001720685","owner_name":"Katabi Maha","owner_display_name":"Katabi Maha","owner_url":"/insider/0001720685","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":340000.0,"shares_display":"340,000","price_per_share":40.5,"price_display":"40.50","price_state":"stated","total_value":13770000.0,"total_display":"13,770,000.00","total_whole":"13,770,000","shares_owned_after":2793987.0,"shares_owned_after_display":"2,793,987","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-25","filed_date":"2024-03-25","scope":"insider"},{"id":2075983,"accession":"0001104659-24-038589","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-24-038589","line_url":"/filing/0001104659-24-038589#line-5","is_derivative":false,"issuer_cik":"0001720685","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001720685","owner_cik":"0001720685","owner_name":"Katabi Maha","owner_display_name":"Katabi Maha","owner_url":"/insider/0001720685","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":413450.0,"shares_display":"413,450","price_per_share":40.51,"price_display":"40.51","price_state":"stated","total_value":16748859.5,"total_display":"16,748,859.50","total_whole":"16,748,860","shares_owned_after":3133987.0,"shares_owned_after_display":"3,133,987","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-22","filed_date":"2024-03-25","scope":"insider"},{"id":2075981,"accession":"0001104659-24-038589","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-24-038589","line_url":"/filing/0001104659-24-038589","is_derivative":false,"issuer_cik":"0001720685","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001720685","owner_cik":"0001720685","owner_name":"Katabi Maha","owner_display_name":"Katabi Maha","owner_url":"/insider/0001720685","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":81009.0,"shares_display":"81,009","price_per_share":44.201546494833906,"price_display":"44.20","price_state":"stated","total_value":3580723.08,"total_display":"3,580,723.08","total_whole":"3,580,723","shares_owned_after":3595690.0,"shares_owned_after_display":"3,595,690","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-21","filed_date":"2024-03-25","scope":"insider","n_lines":4},{"id":3268150,"accession":"0001104659-24-009537","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-009537","line_url":"/filing/0001104659-24-009537#line-1","is_derivative":false,"issuer_cik":"0001720685","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001720685","owner_cik":"0001720685","owner_name":"Katabi Maha","owner_display_name":"Katabi Maha","owner_url":"/insider/0001720685","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":161290.0,"shares_display":"161,290","price_per_share":31.0,"price_display":"31.00","price_state":"stated","total_value":4999990.0,"total_display":"4,999,990.00","total_whole":"4,999,990","shares_owned_after":3628446.0,"shares_owned_after_display":"3,628,446","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-30","filed_date":"2024-02-01","scope":"insider"},{"id":8501860,"accession":"0001209191-23-050305","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-050305","line_url":"/filing/0001209191-23-050305","is_derivative":false,"issuer_cik":"0001720685","issuer_name":"RayzeBio, Inc.","issuer_ticker":"RYZB","issuer_name_source":null,"issuer_url":"/issuer/0001720685","owner_cik":"0001720685","owner_name":"Katabi Maha","owner_display_name":"Katabi Maha","owner_url":"/insider/0001720685","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":472222.0,"shares_display":"472,222","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":8499996.0,"total_display":"8,499,996.00","total_whole":"8,499,996","shares_owned_after":1209764.0,"shares_owned_after_display":"1,209,764","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-21","scope":"insider","n_lines":2},{"id":8601314,"accession":"0001104659-23-014661","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-014661","line_url":"/filing/0001104659-23-014661#line-1","is_derivative":false,"issuer_cik":"0001245624","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001245624","owner_cik":null,"owner_name":"Sofinnova Venture Partners X, L.P.; HEALY JAMES; Sofinnova Management X-A, L.L.C.; Katabi Maha; Sofinnova Management X, L.P.","owner_display_name":"Sofinnova Venture Partners X, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":285714.0,"shares_display":"285,714","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":1999998.0,"total_display":"1,999,998.00","total_whole":"1,999,998","shares_owned_after":3467156.0,"shares_owned_after_display":"3,467,156","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-06","filed_date":"2023-02-08","scope":"insider"},{"id":8494302,"accession":"0001209191-23-013481","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-013481","line_url":"/filing/0001209191-23-013481#line-1","is_derivative":false,"issuer_cik":"0001245624","issuer_name":"CinCor Pharma, Inc.","issuer_ticker":"CINC","issuer_name_source":null,"issuer_url":"/issuer/0001245624","owner_cik":null,"owner_name":"Sofinnova Management X-A, L.L.C.; Sofinnova Venture Partners X, L.P.; HEALY JAMES; Sofinnova Management X, L.P.; Katabi Maha","owner_display_name":"Sofinnova Management X-A, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":14.32,"price_display":"14.32","price_state":"stated","total_value":85920.0,"total_display":"85,920.00","total_whole":"85,920","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-28","filed_date":"2023-02-27","scope":"insider"},{"id":6476371,"accession":"0001104659-22-091184","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-091184","line_url":"/filing/0001104659-22-091184#line-1","is_derivative":false,"issuer_cik":"0001680194","issuer_name":"CinCor Pharma, Inc.","issuer_ticker":"CINC","issuer_name_source":null,"issuer_url":"/issuer/0001680194","owner_cik":null,"owner_name":"Sofinnova Venture Partners X, L.P.; Sofinnova Management X, L.L.C.; Katabi Maha","owner_display_name":"Sofinnova Venture Partners X, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":15000000.0,"total_display":"15,000,000.00","total_whole":"15,000,000","shares_owned_after":6073949.0,"shares_owned_after_display":"6,073,949","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-11","filed_date":"2022-08-15","scope":"insider"},{"id":6397524,"accession":"0001104659-22-023301","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-023301","line_url":"/filing/0001104659-22-023301#line-1","is_derivative":false,"issuer_cik":"0001245624","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001245624","owner_cik":null,"owner_name":"Sofinnova Management X, L.L.C.; Katabi Maha; HEALY JAMES; Sofinnova Venture Partners X, L.P.","owner_display_name":"Sofinnova Management X, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":266666.0,"shares_display":"266,666","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3999990.0,"total_display":"3,999,990.00","total_whole":"3,999,990","shares_owned_after":3181442.0,"shares_owned_after_display":"3,181,442","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-10","filed_date":"2022-02-14","scope":"insider"},{"id":6749608,"accession":"0001209191-22-003197","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-003197","line_url":"/filing/0001209191-22-003197#line-2","is_derivative":false,"issuer_cik":"0001680194","issuer_name":"CinCor Pharma, Inc.","issuer_ticker":"CINC","issuer_name_source":null,"issuer_url":"/issuer/0001680194","owner_cik":null,"owner_name":"Sofinnova Venture Partners X, L.P.; Sofinnova Management X, L.L.C.; Katabi Maha","owner_display_name":"Sofinnova Venture Partners X, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":325000.0,"shares_display":"325,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":5200000.0,"total_display":"5,200,000.00","total_whole":"5,200,000","shares_owned_after":5573949.0,"shares_owned_after_display":"5,573,949","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider"},{"id":5051571,"accession":"0001104659-21-089437","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-21-089437","line_url":"/filing/0001104659-21-089437#line-2","is_derivative":false,"issuer_cik":"0001720685","issuer_name":"Aerovate Therapeutics, Inc.","issuer_ticker":"AVTE","issuer_name_source":null,"issuer_url":"/issuer/0001720685","owner_cik":"0001720685","owner_name":"Katabi Maha","owner_display_name":"Katabi Maha","owner_url":"/insider/0001720685","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":357142.0,"shares_display":"357,142","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":4999988.0,"total_display":"4,999,988.00","total_whole":"4,999,988","shares_owned_after":3758686.0,"shares_owned_after_display":"3,758,686","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-02","filed_date":"2021-07-06","scope":"insider"},{"id":4937295,"accession":"0001209191-21-033812","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-033812","line_url":"/filing/0001209191-21-033812#line-2","is_derivative":false,"issuer_cik":"0001720685","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001720685","owner_cik":"0001720685","owner_name":"Katabi Maha","owner_display_name":"Katabi Maha","owner_url":"/insider/0001720685","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":727272.0,"shares_display":"727,272","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":7999992.0,"total_display":"7,999,992.00","total_whole":"7,999,992","shares_owned_after":2914776.0,"shares_owned_after_display":"2,914,776","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-18","filed_date":"2021-05-18","scope":"insider"},{"id":4843221,"accession":"0001104659-21-016806","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-21-016806","line_url":"/filing/0001104659-21-016806#line-3","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Sofinnova Venture Partners X, L.P.; POWELL MICHAEL; Sofinnova Management X, L.L.C.; Katabi Maha","owner_display_name":"Sofinnova Venture Partners X, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":450000.0,"shares_display":"450,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":9000000.0,"total_display":"9,000,000.00","total_whole":"9,000,000","shares_owned_after":2754437.0,"shares_owned_after_display":"2,754,437","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider"},{"id":2986954,"accession":"0000899243-20-020562","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-020562","line_url":"/filing/0000899243-20-020562#line-2","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Inozyme Pharma, Inc.","issuer_ticker":"INZY","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"HEALY JAMES; Sofinnova Venture Partners X, L.P.; Sofinnova Management X, L.L.C.; Katabi Maha; POWELL MICHAEL","owner_display_name":"HEALY JAMES","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":437500.0,"shares_display":"437,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":7000000.0,"total_display":"7,000,000.00","total_whole":"7,000,000","shares_owned_after":2028308.0,"shares_owned_after_display":"2,028,308","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-07-28","filed_date":"2020-07-28","scope":"insider"},{"id":2142460,"accession":"0001104659-20-080030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-20-080030","line_url":"/filing/0001104659-20-080030#line-3","is_derivative":false,"issuer_cik":"0001202793","issuer_name":"Akouos, Inc.","issuer_ticker":"AKUS","issuer_name_source":null,"issuer_url":"/issuer/0001202793","owner_cik":null,"owner_name":"Sofinnova Management X, L.L.C.; Katabi Maha; HEALY JAMES; Sofinnova Venture Partners X, L.P.; POWELL MICHAEL","owner_display_name":"Sofinnova Management X, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":58823.0,"shares_display":"58,823","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":999991.0,"total_display":"999,991.00","total_whole":"999,991","shares_owned_after":1515073.0,"shares_owned_after_display":"1,515,073","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-30","filed_date":"2020-07-01","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":5,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001831828","name":"Vera Therapeutics, Inc.","url":"/issuer/0001831828","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2021-05-18","last_seen":"2024-03-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001825367","name":"RayzeBio, Inc.","url":"/issuer/0001825367","role":"Director","n_filings":1,"first_seen":"2023-09-21","last_seen":"2023-09-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001868734","name":"CinCor Pharma, Inc.","url":"/issuer/0001868734","role":"Ten percent owner","n_filings":3,"first_seen":"2022-01-13","last_seen":"2023-02-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001798749","name":"Aerovate Therapeutics, Inc.","url":"/issuer/0001798749","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2021-07-06","last_seen":"2021-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001641281","name":"Bolt Biotherapeutics, Inc.","url":"/issuer/0001641281","role":"Ten percent owner","n_filings":1,"first_seen":"2021-02-09","last_seen":"2021-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001693011","name":"Inozyme Pharma, Inc.","url":"/issuer/0001693011","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-28","last_seen":"2020-07-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001722271","name":"Akouos, Inc.","url":"/issuer/0001722271","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-01","last_seen":"2020-07-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001720685","retrieved_at":"2026-08-26T18:20:55+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}